Longevity Drugs

Why human longevity drugs face an impossible patent catch-22

Celine Halioua explains the complex regulatory and business challenges facing human longevity drug development. She discusses the difficulty of designing clinical trials when it's unclear whether to measure direct mortality reduction or leading indicators, and highlights how patent issues create a fundamental catch-22 for developing longevity treatments.